JP2010528620A - 骨髄異形成症候群（ｍｄｓ）に関連する増殖性障害の治療および診断のためのｓａｌｌ４の標的化方法 - Google Patents

骨髄異形成症候群（ｍｄｓ）に関連する増殖性障害の治療および診断のためのｓａｌｌ４の標的化方法 Download PDF

Info

Publication number
JP2010528620A
JP2010528620A JP2010510523A JP2010510523A JP2010528620A JP 2010528620 A JP2010528620 A JP 2010528620A JP 2010510523 A JP2010510523 A JP 2010510523A JP 2010510523 A JP2010510523 A JP 2010510523A JP 2010528620 A JP2010528620 A JP 2010528620A
Authority
JP
Japan
Prior art keywords
sall4
cells
cell
seq
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010510523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010528620A5 (enExample
Inventor
ユポ マ
Original Assignee
ネバダ キャンサー インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネバダ キャンサー インスティテュート filed Critical ネバダ キャンサー インスティテュート
Publication of JP2010528620A publication Critical patent/JP2010528620A/ja
Publication of JP2010528620A5 publication Critical patent/JP2010528620A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G01N33/57505—
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010510523A 2007-06-01 2008-05-30 骨髄異形成症候群（ｍｄｓ）に関連する増殖性障害の治療および診断のためのｓａｌｌ４の標的化方法 Pending JP2010528620A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/809,871 US20080241110A1 (en) 2005-11-29 2007-06-01 Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)
PCT/US2008/065349 WO2008151035A2 (en) 2007-06-01 2008-05-30 Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds)

Publications (2)

Publication Number Publication Date
JP2010528620A true JP2010528620A (ja) 2010-08-26
JP2010528620A5 JP2010528620A5 (enExample) 2011-07-14

Family

ID=40094374

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010510523A Pending JP2010528620A (ja) 2007-06-01 2008-05-30 骨髄異形成症候群（ｍｄｓ）に関連する増殖性障害の治療および診断のためのｓａｌｌ４の標的化方法

Country Status (6)

Country Link
US (1) US20080241110A1 (enExample)
EP (1) EP2167684A4 (enExample)
JP (1) JP2010528620A (enExample)
AU (1) AU2008259976A1 (enExample)
CA (1) CA2690725A1 (enExample)
WO (1) WO2008151035A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017171097A1 (ja) * 2016-04-01 2017-10-05 公益財団法人ヒューマンサイエンス振興財団 未分化細胞間における分化傾向の評価方法、分化傾向の評価マーカーとしてのＳＡＬＬ３ ｍＲＮＡ、及び、未分化細胞の分化能力の制御方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042800A1 (en) * 2008-10-10 2010-04-15 Nevada Cancer Institute Methods of reprogramming somatic cells and methods of use for such cells
CN103124784A (zh) 2010-08-23 2013-05-29 纽约州立大学研究基金会 用于扩增干细胞的方法和这些细胞的用途
SG11201400499PA (en) 2011-09-20 2014-06-27 Brigham & Womens Hospital Sall4 and uses thereof
US20140273016A1 (en) * 2013-03-14 2014-09-18 William Michael Schopperle Device and method for the detection and diagnosis of aggressive and metastatic cancer and cancer stem cells employing podocalyxin and tra biomarkers
WO2019140088A1 (en) * 2018-01-12 2019-07-18 Celgene Corporation Methods for screening cereblon modifying compounds
CN110592211A (zh) * 2019-08-15 2019-12-20 南开大学 基因foxd4在制备急性髓系白血病诊断试剂盒的应用及试剂盒
CN111713450B (zh) * 2020-05-26 2022-07-12 上海交通大学医学院 一种慢性粒细胞白血病的pdx模型的建立方法
CN113142130B (zh) * 2021-03-12 2022-11-04 山东融发生物科技开发有限公司 一种抗病猪的选育方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081592A1 (en) * 2000-03-07 2002-06-27 Whitehead Institute For Biomedical Research Reproduction-specific genes
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
ES2309485T3 (es) * 2003-01-06 2008-12-16 Wyeth Composiciones y procedimientos para diagnosticar y tratar los canceres de colon.
US20050181381A1 (en) * 2003-04-18 2005-08-18 University Of Massachusetts Prognosis, diagnosis and treatment of bone marrow derived stem cell associated cancer
EP2273271A3 (en) * 2004-04-23 2011-04-13 Rigshospitalet, Copenhagen University Hospital Use of novel biomarkers for detection of testicular carcinoma in situ and derived cancers in human samples
US7790407B2 (en) * 2005-11-29 2010-09-07 Nevada Cancer Institute Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017171097A1 (ja) * 2016-04-01 2017-10-05 公益財団法人ヒューマンサイエンス振興財団 未分化細胞間における分化傾向の評価方法、分化傾向の評価マーカーとしてのＳＡＬＬ３ ｍＲＮＡ、及び、未分化細胞の分化能力の制御方法

Also Published As

Publication number Publication date
AU2008259976A1 (en) 2008-12-11
EP2167684A4 (en) 2010-12-29
EP2167684A2 (en) 2010-03-31
US20080241110A1 (en) 2008-10-02
WO2008151035A2 (en) 2008-12-11
WO2008151035A3 (en) 2009-01-29
CA2690725A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
Thomas et al. Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells
Lu et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer
Blume-Jensen et al. Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3′-kinase is essential for male fertility
Liu et al. Bcl11a is essential for normal lymphoid development
US20120030780A1 (en) Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds)
JP2010528620A (ja) 骨髄異形成症候群（ｍｄｓ）に関連する増殖性障害の治療および診断のためのｓａｌｌ４の標的化方法
Caudell et al. Expression of a CALM-AF10 fusion gene leads to Hoxa cluster overexpression and acute leukemia in transgenic mice
Carofino et al. A mouse model for inducible overexpression of Prdm14 results in rapid-onset and highly penetrant T-cell acute lymphoblastic leukemia (T-ALL)
Zhang et al. Notch-regulated periphery B cell differentiation involves suppression of E protein function
Smeets et al. Fli-1 overexpression in hematopoietic progenitors deregulates T cell development and induces pre-T cell lymphoblastic leukaemia/lymphoma
Scherger et al. Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma
Lazorchak et al. E2A promotes the survival of precursor and mature B lymphocytes
JP7069147B2 (ja) 小細胞肺癌患者を特定及び治療するための方法ならびに組成物
Numata et al. Establishment of a transgenic mouse to model ETV7 expressing human tumors
US9091696B2 (en) Modulation of NR2F6 and methods and uses thereof
Bach et al. Premature terminal differentiation protects from deregulated lymphocyte activation by ITK-Syk
Prost et al. The putative tumor suppressor gene EphA7 is a novel BMI-1 target
US20100061973A1 (en) Graded Expression of Snail as Marker of Cancer Development and DNA Damage-Based Diseases
Zimmerman et al. Developmental Stage and Cellular Context Determine Oncogenic and Molecular Outcomes of Ezh2Y641F Mutation in Hematopoiesis
FENG Roles of SETD4 in radiation sensitivity and tumorigenesis
Thompson Development of Transgenic and Allograft Mouse Models of Ependymoma
Kunz Analysis of YBX1 and HUWE1 in MYC-Driven Plasma Cell Neoplasms and Their Therapeutic Potential in Multiple Myeloma
Artibani WT1 role in mammary gland and breast cancer biology
Basheer The Role of EZH2 in the Induction and Maintenance of Acute Myeloid Leukaemia
Spillane Roles of a Putative Tumor Suppressor Gene, Chc1L, in Tumorigenesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110526

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20111012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111012

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20120927